
|Videos|October 27, 2022
Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab
Author(s)Hetty E. Carraway, MD, Eytan M. Stein, MD
Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















